ZG005 added to etoposide and cisplatin for advanced neuroendocrine carcinoma
Tests ZG005 with etoposide and cisplatin in adults with untreated advanced neuroendocrine carcinoma.
Plain-language title generated from the registry record
Registry title: ZG005 Plus Etoposide and Cisplatin vs. Etoposide and Cisplatin as First-Line Treatment for Advanced Neuroendocrine Carcinoma
Key facts
- Where
- Zhengzhou, ChinaSee the site
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07833839, who can take part
Where in China
- The First Affiliated Hospital of Zhengzhou UniversityZhengzhou, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Trial code
- NCT07833839
- Record updated
- 22 September 2026
- Original description
This is a randomized, double-blind, controlled, multicenter Phase III study evaluating the efficacy, safety, pharmacokinetics, and immunogenicity of ZG005 combined with the EP regimen (etoposide plus cisplatin) in participants with advanced NEC who are naive to systemic therapy.Read full original descriptionShow less
A Randomized, Double-Blind, Controlled, Multicenter Phase III Clinical Trial of ZG005 in Combination With Etoposide and Cisplatin Versus Etoposide and Cisplatin as First-Line Treatment for Advanced Neuroendocrine Carcinoma
This is a randomized, double-blind, controlled, multicenter Phase III study evaluating the efficacy, safety, pharmacokinetics, and immunogenicity of ZG005 combined with the EP regimen (etoposide plus cisplatin) in participants with advanced NEC who are naive to systemic therapy.
Inclusion: Participant has fully understood the trial, agrees to comply with the study treatment regimen and visit schedule, and voluntarily signs the informed consent form (ICF); Male or female participants aged 18 to 75 years (inclusive) at the time of signing the informed consent form (ICF); Life expectancy of more than 3 months; Histologically confirmed recurrent or metastatic neuroendocrine carcinoma (NEC); The Eastern Cooperative Oncology Group's physical status scoring standard (ECOG) is 0~1.
Exclusion: History, computed tomography (CT), or magnetic resonance imaging (MRI) findings suggestive of central nervous system (CNS) metastases or leptomeningeal metastases.